{"protocolSection": {"identificationModule": {"nctId": "NCT02172040", "orgStudyIdInfo": {"id": "KIT-302-03-01"}, "secondaryIdInfos": [{"id": "2013-005381-19", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "KitovPharma", "class": "UNKNOWN"}, "briefTitle": "Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects With Hypertension Requiring Antihypertensive Therapy", "officialTitle": "A Prospective Randomized Placebo Controlled Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects With Hypertension Requiring Antihypertensive Therapy"}, "statusModule": {"statusVerifiedDate": "2018-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-06-26", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2015-11-19", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-11-19", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-06-20", "studyFirstSubmitQcDate": "2014-06-23", "studyFirstPostDateStruct": {"date": "2014-06-24", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-07-31", "resultsFirstSubmitQcDate": "2017-09-29", "resultsFirstPostDateStruct": {"date": "2017-10-03", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-09-11", "lastUpdatePostDateStruct": {"date": "2018-10-10", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Kitov Pharmaceuticals, Ltd.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study was to evaluate the effect of celecoxib on the efficacy and safety of amlodipine besylate in subjects with newly diagnosed hypertension requiring antihypertensive therapy.\n\nThis study was conducted to support a future marketing application for KIT-302. Kitov Pharma Ltd. (Kitov) is developing KIT-302, an oral fixed combination drug product (FCDP) consisting of the calcium channel blocker amlodipine besylate and the nonsteroidal anti-inflammatory drug (NSAID) celecoxib, as a \"convenience reformulation\" FCDP to facilitate and improve patient compliance with the once a day (qd) administration of its individual components, amlodipine and celecoxib.\n\nThe formulation of KIT-302 consists of amlodipine besylate and celecoxib co-formulated in a single immediate release tablet. However, for this study, two separate capsules were utilized: one containing a commercial celecoxib capsule (Celebrex\u00ae) or matched placebo capsule and one containing a commercial amlodipine besylate tablet (Norvasc\u00ae) or matched placebo tablet.\n\nThe study hypothesis was that treatment with the amlodipine besylate containing capsule plus the celecoxib containing capsule would reduce blood pressure (BP) in subjects with hypertension with an efficacy that is not substantially inferior to the effect of amlodipine besylate alone (i.e., the amlodipine containing capsule plus the matched placebo for the celecoxib capsule).\n\nThe United States (US) Food and Drug Administration (FDA) recently approved KIT-302, under the brand name Consensi\u00ae (amlodipine and celecoxib) tablets \\[New Drug Application (NDA) 210045\\] for the following indication: \"patients for whom treatment with amlodipine for hypertension and celecoxib for osteoarthritis are appropriate. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.\""}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["High blood pressure", "Systolic blood pressure", "Diastolic blood pressure", "Antihypertensive"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 152, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Amlodipine+Celecoxib", "type": "EXPERIMENTAL", "description": "Over-encapsulated 10 mg amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks", "interventionNames": ["Drug: Over-encapsulated 10 mg amlodipine besylate tablet", "Drug: Over-encapsulated 200 mg celecoxib capsule"]}, {"label": "Amlodipine+Placebo", "type": "ACTIVE_COMPARATOR", "description": "Over-encapsulated 10 mg amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks", "interventionNames": ["Drug: Over-encapsulated 10 mg amlodipine besylate tablet", "Drug: Matched placebo capsule for over-encapsulated celecoxib capsule"]}, {"label": "Placebo+Celecoxib", "type": "PLACEBO_COMPARATOR", "description": "Matched placebo capsule for over-encapsulated amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks", "interventionNames": ["Drug: Over-encapsulated 200 mg celecoxib capsule", "Drug: Matched placebo capsule for over-encapsulated amlodipine besylate tablet"]}, {"label": "Placebo+Placebo", "type": "SHAM_COMPARATOR", "description": "Matched placebo capsule for over-encapsulated amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks", "interventionNames": ["Drug: Matched placebo capsule for over-encapsulated celecoxib capsule", "Drug: Matched placebo capsule for over-encapsulated amlodipine besylate tablet"]}], "interventions": [{"type": "DRUG", "name": "Over-encapsulated 10 mg amlodipine besylate tablet", "description": "Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks", "armGroupLabels": ["Amlodipine+Celecoxib", "Amlodipine+Placebo"], "otherNames": ["Norvasc"]}, {"type": "DRUG", "name": "Matched placebo capsule for over-encapsulated celecoxib capsule", "description": "Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks", "armGroupLabels": ["Amlodipine+Placebo", "Placebo+Placebo"], "otherNames": ["Placebo"]}, {"type": "DRUG", "name": "Over-encapsulated 200 mg celecoxib capsule", "description": "Over-encapsulated 200 mg celecoxib capsule once a day for two weeks", "armGroupLabels": ["Amlodipine+Celecoxib", "Placebo+Celecoxib"], "otherNames": ["Celebrex"]}, {"type": "DRUG", "name": "Matched placebo capsule for over-encapsulated amlodipine besylate tablet", "description": "Matched placebo capsule for over-encapsulated amlodipine besylate tablet once a day for two weeks", "armGroupLabels": ["Placebo+Celecoxib", "Placebo+Placebo"], "otherNames": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Mean Change in Average Daytime (9:00 to 21:00) Ambulatory Systolic Blood Pressure (SBPday) - Primary Endpoint", "timeFrame": "Baseline and 2 weeks"}, {"measure": "Frequency of Adverse Events (Number of Participants Affected/Number of Participants at Risk)", "description": "Including any untoward medical occurrence in a participant administered study drug, which do not necessarily have a causal relationship with the study drug \\[i.e., any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug, whether or not related to the study drug\\].", "timeFrame": "1 month"}], "secondaryOutcomes": [{"measure": "Mean Change in Average 24-hour Ambulatory Systolic Blood Pressure (SBP24h)", "timeFrame": "Baseline and 2 weeks"}, {"measure": "Mean Change in Average Night-time (01:00 to 06:00) Ambulatory Systolic Blood Pressure (SBPnight)", "timeFrame": "Baseline and 2 weeks"}, {"measure": "Mean Change in Average 24-hour Ambulatory Diastolic Blood Pressure (DBP24h)", "timeFrame": "Baseline and 2 weeks"}, {"measure": "Mean Change in Average Daytime (9:00 to 21:00) Ambulatory Diastolic Blood Pressure (DBPday)", "timeFrame": "Baseline and 2 weeks"}, {"measure": "Mean Change in Average Night-time (01:00 to 06:00) Ambulatory Diastolic Blood Pressure (DBPnight)", "timeFrame": "Baseline and 2 weeks"}, {"measure": "Mean Non-transformed Amlodipine Plasma Concentration", "timeFrame": "24 hours post-dose on Day 14"}, {"measure": "Mean Non-transformed Celecoxib Plasma Concentration", "timeFrame": "24 hours post-dose on Day 14"}, {"measure": "Mean Log-transformed Amlodipine Plasma Concentration", "timeFrame": "24 hours post-dose on Day 14"}, {"measure": "Mean Log-transformed Celecoxib Plasma Concentration", "timeFrame": "24 hours post-dose on Day 14"}, {"measure": "Mean Change in Average Daytime (9:00 to 21:00) Ambulatory Systolic Blood Pressure (SBPday) - Secondary Endpoint", "timeFrame": "Baseline and 2 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Adult 40 to 75 years of age\n2. Newly diagnosed hypertension that requires chronic pharmacological therapy. Specifically, the subject must meet both of the following criteria:\n\n   1. Resting systolic BP \u2265140 mmHg and \u2264179 mmHg (where resting is defined as supine for at least 10 minutes with minimal interaction) at Initial Screening Visit\n   2. SBPday \\>135 mmHg at Baseline Visit (Day 0)\n3. Body Mass Index of 18.5 to 34.9 kg/m2\n4. Healthy (other than hypertension) as determined by the Investigator based on medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory tests\n5. A negative pregnancy test at Screening\n6. Both males and women of child bearing potential agree to use adequate contraceptive methods while on study (from Screening through final study visit)\n7. Able to comprehend and sign an informed consent form\n\nExclusion Criteria:\n\n1. Resting systolic BP \\>179 mmHg or a resting diastolic BP \\>110 mmHg at Screening (where resting is defined as supine for at least 10 minutes with minimal interaction) or SBP24h \\>169 mmHg or DBP24h \\>110 mmHg at randomization\n2. SBPday \u2264135 mmHg at baseline (Day 0)\n3. Weight \\<55 kg\n4. Fragile health\n5. Evidence of clinically significant findings on screening evaluations (clinical, laboratory, and ECG) which, in the opinion of the Investigator would pose a safety risk or interfere with appropriate interpretation of safety data\n6. Current or recent history (within 4 weeks prior to Screening) of a clinically significant bacterial, fungal, or mycobacterial infection\n7. Current clinically significant viral infection\n8. History of malignancy, with the exception of cured basal cell or squamous cell carcinoma of the skin\n9. Major surgery within 4 weeks prior to Screening\n10. Presence of a malabsorption syndrome possibly affecting drug absorption (e.g., Crohn's disease or chronic pancreatitis)\n11. Active peptic ulceration or history of gastrointestinal bleeding\n12. History of myocardial infarction, congestive heart failure, or stroke\n13. Any current cardiovascular disease\n14. History of psychotic disorder\n15. History of alcoholism or drug addiction or current alcohol or drug use that, in the opinion of the Investigator, will interfere with the subject's ability to comply with the dosing schedule and study evaluations\n16. History of any illicit drug use within one year prior to Screening\n17. Positive drug screen at Screening. A positive drug screen for opiates only (with all other drug tests negative) will not be a basis for exclusion if the subject took over-the-counter narcotics as indicated on the product label within 24 hours prior to the drug screen\n18. Current treatment or treatment within 30 days prior to first dose of study drugs with another investigational drug or current enrollment in another clinical trial\n19. Current treatment or treatment within 30 days prior to first dose of study drugs with an NSAID or systemic corticosteroid\n20. Known history of human immunodeficiency virus, hepatitis B, or hepatitis C\n21. Known hypersensitivity to amlodipine or celecoxib\n22. Known hypersensitivity to the inactive ingredients in the over-encapsulated study drugs\n23. Asthma, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria or other allergic type reactions after taking acetylsalicylic acid or NSAIDs including cyclooxygenase-2 inhibitors\n24. Subjects who, in the opinion of the Investigator, are unable or unlikely to comply with the dosing schedule and study evaluations\n25. Pregnant or lactating\n26. Unable to correctly use ambulatory blood pressure monitor after instruction on its use\n27. Subjects with Child-Pugh Class B or C cirrhosis;\n28. Subjects currently taking a calcium channel blocker for any reason including angina. Subjects will not be withdrawn from these drugs to be enrolled in the trial\n29. Creatinine clearance \\<50 ml/min as estimated by the Cockroft-Gault equation\n30. Known cytochrome P450 2C9 poor metabolizer\n31. Subjects with allergy or hypersensitivity to sulfonamides", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "40 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "J. Paul Waymack, MD, ScD", "affiliation": "Kitov Pharma Ltd", "role": "STUDY_DIRECTOR"}, {"name": "Brendan Colgan, MD", "affiliation": "Celerion", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Claire Kightley, MB", "affiliation": "Reading Clinical Research Aspect", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "David Collier, MBBS, PhD, BSc", "affiliation": "Barts Health NHS Trust, William Harvey Heart Centre, Barts & The London, Queen Mary School of Medicine and Dentistry, Queen Mary, University of London", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Paul Ivan, MBBS", "affiliation": "Synexus Merseyside Clinical Research Centre", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Veronika Horvathova, MD", "affiliation": "Synexus Scotland Clinical Research Centre", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Amit Mathew, MS, MBBS", "affiliation": "Synexus Midlands Clinical Research Centre", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Alexander Thompson, MB, BS, DRCOG", "affiliation": "Reading Clinical Research Aspect", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Mohamed Okily, MB", "affiliation": "Synexus Manchester Clinical Research Centre", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Richard Gaunt, MB, ChB, MRCGP, DRCOG", "affiliation": "Rowden Surgery", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Patrick Eavis, MBBS, DRCOG, DFFP, MRCGP", "affiliation": "Oldfield Surgery", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Arjun Ravi, MBBS, MRCP", "affiliation": "The Medicines Evaluation Unit Ltd.", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Celerion", "city": "Belfast", "state": "Antrim", "zip": "BT9 6AD", "country": "United Kingdom", "geoPoint": {"lat": 54.59682, "lon": -5.92541}}, {"facility": "The Medicines Evaluation Unit Ltd.", "city": "Manchester", "state": "Greater Manchester", "zip": "M23 9QZ", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "Reading Clinical Research Aspect", "city": "Ledbury", "state": "Herefordshire", "zip": "HR8 2AA", "country": "United Kingdom", "geoPoint": {"lat": 52.03639, "lon": -2.42635}}, {"facility": "Synexus Merseyside Clinical Research Centre", "city": "Liverpool", "state": "Merseyside", "zip": "L22 0LG", "country": "United Kingdom", "geoPoint": {"lat": 53.41058, "lon": -2.97794}}, {"facility": "Oldfield Surgery", "city": "Bath", "state": "North East Somerset", "zip": "BA2 3HT", "country": "United Kingdom", "geoPoint": {"lat": 51.3751, "lon": -2.36172}}, {"facility": "Rowden Surgery", "city": "Chippenham", "state": "Wiltshire", "zip": "SN15 2SB", "country": "United Kingdom", "geoPoint": {"lat": 51.46, "lon": -2.12472}}, {"facility": "Synexus Midlands Clinical Research Centre", "city": "Birmingham", "zip": "B15 2SQ", "country": "United Kingdom", "geoPoint": {"lat": 52.48142, "lon": -1.89983}}, {"facility": "Synexus Scotland Clinical Research Centre", "city": "Glasgow", "zip": "G20 0SP", "country": "United Kingdom", "geoPoint": {"lat": 55.86515, "lon": -4.25763}}, {"facility": "Barts Health NHS Trust, William Harvey Heart Centre, Barts & The London, Queen Mary School of Medicine and Dentistry, Queen Mary, University of London", "city": "London", "zip": "EC1M 6BQ", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"facility": "Reading Clinical Research Aspect", "city": "Reading", "zip": "RG6 6BZ", "country": "United Kingdom", "geoPoint": {"lat": 51.45625, "lon": -0.97113}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants underwent assessments to determine eligibility at the Initial Screening Visit (Day -7 to -2; 458 participants), Final Screening Visit (Day -1; 228 participants), and the morning prior to randomization (Study Day 0; 227 participants). A total of 306 participants were screen failures and the remaining 152 were randomized.", "groups": [{"id": "FG000", "title": "Amlodipine+Celecoxib", "description": "Over-encapsulated 10 mg amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nOver-encapsulated 10 mg amlodipine besylate tablet: Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks\n\nOver-encapsulated 200 mg celecoxib capsule: Over-encapsulated 200 mg celecoxib capsule once a day for two weeks"}, {"id": "FG001", "title": "Amlodipine+Placebo", "description": "Over-encapsulated 10 mg amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks\n\nOver-encapsulated 10 mg amlodipine besylate tablet: Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks\n\nMatched placebo capsule for over-encapsulated celecoxib capsule: Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks"}, {"id": "FG002", "title": "Placebo+Celecoxib", "description": "Matched placebo tablet for over-encapsulated amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nOver-encapsulated 200 mg celecoxib capsule: Over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nMatched placebo tablet for over-encapsulated amlodipine besylate tablet: Matched placebo tablet for over-encapsulated amlodipine besylate tablet once a day for two weeks"}, {"id": "FG003", "title": "Placebo+Placebo", "description": "Matched placebo tablet for over-encapsulated amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks\n\nMatched placebo capsule for over-encapsulated celecoxib capsule: Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks\n\nMatched placebo tablet for over-encapsulated amlodipine besylate tablet: Matched placebo tablet for over-encapsulated amlodipine besylate tablet once a day for two weeks"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "49"}, {"groupId": "FG001", "numSubjects": "45"}, {"groupId": "FG002", "numSubjects": "31"}, {"groupId": "FG003", "numSubjects": "27"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "49"}, {"groupId": "FG001", "numSubjects": "42"}, {"groupId": "FG002", "numSubjects": "29"}, {"groupId": "FG003", "numSubjects": "26"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Not available for Day 13 & 14 visits", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Family emergency abroad", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Amlodipine+Celecoxib", "description": "Over-encapsulated 10 mg amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nOver-encapsulated 10 mg amlodipine besylate tablet: Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks\n\nOver-encapsulated 200 mg celecoxib capsule: Over-encapsulated 200 mg celecoxib capsule once a day for two weeks"}, {"id": "BG001", "title": "Amlodipine+Placebo", "description": "Over-encapsulated 10 mg amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks\n\nOver-encapsulated 10 mg amlodipine besylate tablet: Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks\n\nMatched placebo capsule for over-encapsulated celecoxib capsule: Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks"}, {"id": "BG002", "title": "Placebo+Celecoxib", "description": "Matched placebo tablet for over-encapsulated amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nOver-encapsulated 200 mg celecoxib capsule: Over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nMatched placebo tablet for over-encapsulated amlodipine besylate tablet: Matched placebo tablet for over-encapsulated amlodipine besylate tablet once a day for two weeks"}, {"id": "BG003", "title": "Placebo+Placebo", "description": "Matched placebo tablet for over-encapsulated amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks\n\nMatched placebo capsule for over-encapsulated celecoxib capsule: Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks\n\nMatched placebo tablet for over-encapsulated amlodipine besylate tablet: Matched placebo tablet for over-encapsulated amlodipine besylate tablet once a day for two weeks"}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "49"}, {"groupId": "BG001", "value": "45"}, {"groupId": "BG002", "value": "31"}, {"groupId": "BG003", "value": "27"}, {"groupId": "BG004", "value": "152"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "57.7", "spread": "8.0"}, {"groupId": "BG001", "value": "57.3", "spread": "9.4"}, {"groupId": "BG002", "value": "54.9", "spread": "8.2"}, {"groupId": "BG003", "value": "52.5", "spread": "9.1"}, {"groupId": "BG004", "value": "56.1", "spread": "8.8"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "10"}, {"groupId": "BG003", "value": "10"}, {"groupId": "BG004", "value": "56"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "32"}, {"groupId": "BG001", "value": "26"}, {"groupId": "BG002", "value": "21"}, {"groupId": "BG003", "value": "17"}, {"groupId": "BG004", "value": "96"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "5"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "3"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "46"}, {"groupId": "BG001", "value": "43"}, {"groupId": "BG002", "value": "29"}, {"groupId": "BG003", "value": "26"}, {"groupId": "BG004", "value": "144"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "United Kingdom", "categories": [{"measurements": [{"groupId": "BG000", "value": "49"}, {"groupId": "BG001", "value": "45"}, {"groupId": "BG002", "value": "31"}, {"groupId": "BG003", "value": "27"}, {"groupId": "BG004", "value": "152"}]}]}]}, {"title": "Average Daytime (9:00 to 21:00) Ambulatory Systolic Blood Pressure (SBPday)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmHg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "148.7", "spread": "7.4"}, {"groupId": "BG001", "value": "147.6", "spread": "8.7"}, {"groupId": "BG002", "value": "150.8", "spread": "8.9"}, {"groupId": "BG003", "value": "147.3", "spread": "8.6"}, {"groupId": "BG004", "value": "148.5", "spread": "8.4"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Mean Change in Average Daytime (9:00 to 21:00) Ambulatory Systolic Blood Pressure (SBPday) - Primary Endpoint", "populationDescription": "Intent-to-treat (ITT): All randomized participants who received at least 1 dose of study drug and had at least a valid baseline ambulatory blood pressure monitor measurement (ABPM) and either: a) a valid Day 13-14 ABPM, where participant completed treatment or b) a valid Day 6-7 or Day 0-1 ABPM, where participant was withdrawn early.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and 2 weeks", "groups": [{"id": "OG000", "title": "Amlodipine+Celecoxib", "description": "Over-encapsulated 10 mg amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nOver-encapsulated 10 mg amlodipine besylate tablet: Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks\n\nOver-encapsulated 200 mg celecoxib capsule: Over-encapsulated 200 mg celecoxib capsule once a day for two weeks"}, {"id": "OG001", "title": "Amlodipine+Placebo", "description": "Over-encapsulated 10 mg amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks\n\nOver-encapsulated 10 mg amlodipine besylate tablet: Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks\n\nMatched placebo capsule for over-encapsulated celecoxib capsule: Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks"}, {"id": "OG002", "title": "Placebo+Celecoxib", "description": "Matched placebo tablet for over-encapsulated amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nOver-encapsulated 200 mg celecoxib capsule: Over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nMatched placebo tablet for over-encapsulated amlodipine besylate tablet: Matched placebo tablet for over-encapsulated amlodipine besylate tablet once a day for two weeks"}, {"id": "OG003", "title": "Placebo+Placebo", "description": "Matched placebo tablet for over-encapsulated amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks\n\nMatched placebo capsule for over-encapsulated celecoxib capsule: Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks\n\nMatched placebo tablet for over-encapsulated amlodipine besylate tablet: Matched placebo tablet for over-encapsulated amlodipine besylate tablet once a day for two weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "45"}, {"groupId": "OG002", "value": "30"}, {"groupId": "OG003", "value": "26"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-10.6", "spread": "9.2"}, {"groupId": "OG001", "value": "-8.83", "spread": "8.13"}, {"groupId": "OG002", "value": "-0.5", "spread": "8.8"}, {"groupId": "OG003", "value": "-2.11", "spread": "8.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "A serial gatekeeping strategy was used for the primary efficacy endpoint analysis. The primary comparison was a two-sample t-test to test the one-sided hypothesis that treatment with amlodipine + celecoxib was non-inferior to half of the effect achieved with amlodipine.", "nonInferiorityType": "NON_INFERIORITY", "nonInferiorityComment": "Non-inferiority margin definition: lower limit of the 95% confidence interval (CI) for amlodipine + celecoxib arm did not cross the 50% value for the amlodipine arm.", "pValue": "= 0.001", "statisticalMethod": "t-test, 1 sided"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "A serial gatekeeping strategy was used for the primary efficacy endpoint analysis. The secondary comparison was a two-sample t-test to test the one-sided hypothesis that treatment with placebo was superior to treatment with celecoxib. This was only to be performed if statistical significance was achieved for the primary comparison.", "nonInferiorityType": "SUPERIORITY", "pValue": "= 0.491", "statisticalMethod": "t-test, 1 sided"}]}, {"type": "PRIMARY", "title": "Frequency of Adverse Events (Number of Participants Affected/Number of Participants at Risk)", "description": "Including any untoward medical occurrence in a participant administered study drug, which do not necessarily have a causal relationship with the study drug \\[i.e., any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug, whether or not related to the study drug\\].", "populationDescription": "Safety population: all randomized participants who received at least one dose of study drug.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "1 month", "groups": [{"id": "OG000", "title": "Amlodipine+Celecoxib", "description": "Over-encapsulated 10 mg amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nOver-encapsulated 10 mg amlodipine besylate tablet: Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks\n\nOver-encapsulated 200 mg celecoxib capsule: Over-encapsulated 200 mg celecoxib capsule once a day for two weeks"}, {"id": "OG001", "title": "Amlodipine+Placebo", "description": "Over-encapsulated 10 mg amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks\n\nOver-encapsulated 10 mg amlodipine besylate tablet: Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks\n\nMatched placebo capsule for over-encapsulated celecoxib capsule: Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks"}, {"id": "OG002", "title": "Placebo+Celecoxib", "description": "Matched placebo tablet for over-encapsulated amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nOver-encapsulated 200 mg celecoxib capsule: Over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nMatched placebo tablet for over-encapsulated amlodipine besylate tablet: Matched placebo tablet for over-encapsulated amlodipine besylate tablet once a day for two weeks"}, {"id": "OG003", "title": "Placebo+Placebo", "description": "Matched placebo tablet for over-encapsulated amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks\n\nMatched placebo capsule for over-encapsulated celecoxib capsule: Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks\n\nMatched placebo tablet for over-encapsulated amlodipine besylate tablet: Matched placebo tablet for over-encapsulated amlodipine besylate tablet once a day for two weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "45"}, {"groupId": "OG002", "value": "31"}, {"groupId": "OG003", "value": "27"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "28"}, {"groupId": "OG002", "value": "14"}, {"groupId": "OG003", "value": "10"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002", "OG003"], "nonInferiorityType": "OTHER", "pValue": "= 0.166", "statisticalMethod": "Chi-squared"}]}, {"type": "SECONDARY", "title": "Mean Change in Average 24-hour Ambulatory Systolic Blood Pressure (SBP24h)", "populationDescription": "ITT population as described for primary outcome", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and 2 weeks", "groups": [{"id": "OG000", "title": "Amlodipine+Celecoxib", "description": "Over-encapsulated 10 mg amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nOver-encapsulated 10 mg amlodipine besylate tablet: Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks\n\nOver-encapsulated 200 mg celecoxib capsule: Over-encapsulated 200 mg celecoxib capsule once a day for two weeks"}, {"id": "OG001", "title": "Amlodipine+Placebo", "description": "Over-encapsulated 10 mg amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks\n\nOver-encapsulated 10 mg amlodipine besylate tablet: Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks\n\nMatched placebo capsule for over-encapsulated celecoxib capsule: Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks"}, {"id": "OG002", "title": "Placebo+Celecoxib", "description": "Matched placebo tablet for over-encapsulated amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nOver-encapsulated 200 mg celecoxib capsule: Over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nMatched placebo tablet for over-encapsulated amlodipine besylate tablet: Matched placebo tablet for over-encapsulated amlodipine besylate tablet once a day for two weeks"}, {"id": "OG003", "title": "Placebo+Placebo", "description": "Matched placebo tablet for over-encapsulated amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks\n\nMatched placebo capsule for over-encapsulated celecoxib capsule: Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks\n\nMatched placebo tablet for over-encapsulated amlodipine besylate tablet: Matched placebo tablet for over-encapsulated amlodipine besylate tablet once a day for two weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "45"}, {"groupId": "OG002", "value": "30"}, {"groupId": "OG003", "value": "26"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-10.3", "spread": "8.9"}, {"groupId": "OG001", "value": "-8.02", "spread": "7.6"}, {"groupId": "OG002", "value": "-0.5", "spread": "7.8"}, {"groupId": "OG003", "value": "-1.19", "spread": "5.87"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.177", "statisticalMethod": "t-test, 1 sided"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "t-test, 1 sided"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "t-test, 1 sided"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "t-test, 1 sided"}, {"groupIds": ["OG001", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "t-test, 1 sided"}, {"groupIds": ["OG002", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "= 0.719", "statisticalMethod": "t-test, 1 sided"}]}, {"type": "SECONDARY", "title": "Mean Change in Average Night-time (01:00 to 06:00) Ambulatory Systolic Blood Pressure (SBPnight)", "populationDescription": "ITT Population as described for primary outcome", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and 2 weeks", "groups": [{"id": "OG000", "title": "Amlodipine+Celecoxib", "description": "Over-encapsulated 10 mg amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nOver-encapsulated 10 mg amlodipine besylate tablet: Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks\n\nOver-encapsulated 200 mg celecoxib capsule: Over-encapsulated 200 mg celecoxib capsule once a day for two weeks"}, {"id": "OG001", "title": "Amlodipine+Placebo", "description": "Over-encapsulated 10 mg amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks\n\nOver-encapsulated 10 mg amlodipine besylate tablet: Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks\n\nMatched placebo capsule for over-encapsulated celecoxib capsule: Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks"}, {"id": "OG002", "title": "Placebo+Celecoxib", "description": "Matched placebo tablet for over-encapsulated amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nOver-encapsulated 200 mg celecoxib capsule: Over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nMatched placebo tablet for over-encapsulated amlodipine besylate tablet: Matched placebo tablet for over-encapsulated amlodipine besylate tablet once a day for two weeks"}, {"id": "OG003", "title": "Placebo+Placebo", "description": "Matched placebo tablet for over-encapsulated amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks\n\nMatched placebo capsule for over-encapsulated celecoxib capsule: Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks\n\nMatched placebo tablet for over-encapsulated amlodipine besylate tablet: Matched placebo tablet for over-encapsulated amlodipine besylate tablet once a day for two weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "45"}, {"groupId": "OG002", "value": "30"}, {"groupId": "OG003", "value": "26"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-10.5", "spread": "10.6"}, {"groupId": "OG001", "value": "-6.35", "spread": "11.35"}, {"groupId": "OG002", "value": "-1.7", "spread": "12.3"}, {"groupId": "OG003", "value": "-1.42", "spread": "9.15"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "= 0.069", "statisticalMethod": "t-test, 1 sided"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "= 0.001", "statisticalMethod": "t-test, 1 sided"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "t-test, 1 sided"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "= 0.097", "statisticalMethod": "t-test, 1 sided"}, {"groupIds": ["OG001", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "= 0.064", "statisticalMethod": "t-test, 1 sided"}, {"groupIds": ["OG002", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "= 0.924", "statisticalMethod": "t-test, 1 sided"}]}, {"type": "SECONDARY", "title": "Mean Change in Average 24-hour Ambulatory Diastolic Blood Pressure (DBP24h)", "populationDescription": "ITT Population as described for primary outcome", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and 2 weeks", "groups": [{"id": "OG000", "title": "Amlodipine+Celecoxib", "description": "Over-encapsulated 10 mg amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nOver-encapsulated 10 mg amlodipine besylate tablet: Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks\n\nOver-encapsulated 200 mg celecoxib capsule: Over-encapsulated 200 mg celecoxib capsule once a day for two weeks"}, {"id": "OG001", "title": "Amlodipine+Placebo", "description": "Over-encapsulated 10 mg amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks\n\nOver-encapsulated 10 mg amlodipine besylate tablet: Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks\n\nMatched placebo capsule for over-encapsulated celecoxib capsule: Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks"}, {"id": "OG002", "title": "Placebo+Celecoxib", "description": "Matched placebo tablet for over-encapsulated amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nOver-encapsulated 200 mg celecoxib capsule: Over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nMatched placebo tablet for over-encapsulated amlodipine besylate tablet: Matched placebo tablet for over-encapsulated amlodipine besylate tablet once a day for two weeks"}, {"id": "OG003", "title": "Placebo+Placebo", "description": "Matched placebo tablet for over-encapsulated amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks\n\nMatched placebo capsule for over-encapsulated celecoxib capsule: Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks\n\nMatched placebo tablet for over-encapsulated amlodipine besylate tablet: Matched placebo tablet for over-encapsulated amlodipine besylate tablet once a day for two weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "45"}, {"groupId": "OG002", "value": "30"}, {"groupId": "OG003", "value": "26"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-7.1", "spread": "5.6"}, {"groupId": "OG001", "value": "-4.8", "spread": "4.83"}, {"groupId": "OG002", "value": "-0.5", "spread": "4.6"}, {"groupId": "OG003", "value": "0.22", "spread": "4.28"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "= 0.038", "statisticalMethod": "t-test, 1 sided"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "t-test, 1 sided"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "t-test, 1 sided"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "t-test, 1 sided"}, {"groupIds": ["OG001", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "t-test, 1 sided"}, {"groupIds": ["OG002", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "= 0.562", "statisticalMethod": "t-test, 1 sided"}]}, {"type": "SECONDARY", "title": "Mean Change in Average Daytime (9:00 to 21:00) Ambulatory Diastolic Blood Pressure (DBPday)", "populationDescription": "ITT Population as described for primary outcome", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and 2 weeks", "groups": [{"id": "OG000", "title": "Amlodipine+Celecoxib", "description": "Over-encapsulated 10 mg amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nOver-encapsulated 10 mg amlodipine besylate tablet: Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks\n\nOver-encapsulated 200 mg celecoxib capsule: Over-encapsulated 200 mg celecoxib capsule once a day for two weeks"}, {"id": "OG001", "title": "Amlodipine+Placebo", "description": "Over-encapsulated 10 mg amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks\n\nOver-encapsulated 10 mg amlodipine besylate tablet: Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks\n\nMatched placebo capsule for over-encapsulated celecoxib capsule: Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks"}, {"id": "OG002", "title": "Placebo+Celecoxib", "description": "Matched placebo tablet for over-encapsulated amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nOver-encapsulated 200 mg celecoxib capsule: Over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nMatched placebo tablet for over-encapsulated amlodipine besylate tablet: Matched placebo tablet for over-encapsulated amlodipine besylate tablet once a day for two weeks"}, {"id": "OG003", "title": "Placebo+Placebo", "description": "Matched placebo tablet for over-encapsulated amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks\n\nMatched placebo capsule for over-encapsulated celecoxib capsule: Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks\n\nMatched placebo tablet for over-encapsulated amlodipine besylate tablet: Matched placebo tablet for over-encapsulated amlodipine besylate tablet once a day for two weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "45"}, {"groupId": "OG002", "value": "30"}, {"groupId": "OG003", "value": "26"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-7.5", "spread": "6.4"}, {"groupId": "OG001", "value": "-5.53", "spread": "5.06"}, {"groupId": "OG002", "value": "-1.5", "spread": "5.6"}, {"groupId": "OG003", "value": "-0.32", "spread": "5.39"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "= 0.104", "statisticalMethod": "t-test, 1 sided"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "t-test, 1 sided"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "t-test, 1 sided"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "= 0.002", "statisticalMethod": "t-test, 1 sided"}, {"groupIds": ["OG001", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "t-test, 1 sided"}, {"groupIds": ["OG002", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "= 0.419", "statisticalMethod": "t-test, 1 sided"}]}, {"type": "SECONDARY", "title": "Mean Change in Average Night-time (01:00 to 06:00) Ambulatory Diastolic Blood Pressure (DBPnight)", "populationDescription": "ITT Population as defined for primary outcome", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and 2 weeks", "groups": [{"id": "OG000", "title": "Amlodipine+Celecoxib", "description": "Over-encapsulated 10 mg amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nOver-encapsulated 10 mg amlodipine besylate tablet: Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks\n\nOver-encapsulated 200 mg celecoxib capsule: Over-encapsulated 200 mg celecoxib capsule once a day for two weeks"}, {"id": "OG001", "title": "Amlodipine+Placebo", "description": "Over-encapsulated 10 mg amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks\n\nOver-encapsulated 10 mg amlodipine besylate tablet: Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks\n\nMatched placebo capsule for over-encapsulated celecoxib capsule: Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks"}, {"id": "OG002", "title": "Placebo+Celecoxib", "description": "Matched placebo tablet for over-encapsulated amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nOver-encapsulated 200 mg celecoxib capsule: Over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nMatched placebo tablet for over-encapsulated amlodipine besylate tablet: Matched placebo tablet for over-encapsulated amlodipine besylate tablet once a day for two weeks"}, {"id": "OG003", "title": "Placebo+Placebo", "description": "Matched placebo tablet for over-encapsulated amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks\n\nMatched placebo capsule for over-encapsulated celecoxib capsule: Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks\n\nMatched placebo tablet for over-encapsulated amlodipine besylate tablet: Matched placebo tablet for over-encapsulated amlodipine besylate tablet once a day for two weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "45"}, {"groupId": "OG002", "value": "30"}, {"groupId": "OG003", "value": "26"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-7.0", "spread": "8.6"}, {"groupId": "OG001", "value": "-3.23", "spread": "7.79"}, {"groupId": "OG002", "value": "0.3", "spread": "7.1"}, {"groupId": "OG003", "value": "0.01", "spread": "6.23"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "= 0.028", "statisticalMethod": "t-test, 1 sided"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "t-test, 1 sided"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "t-test, 1 sided"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "= 0.051", "statisticalMethod": "t-test, 1 sided"}, {"groupIds": ["OG001", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "= 0.074", "statisticalMethod": "t-test, 1 sided"}, {"groupIds": ["OG002", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "= 0.878", "statisticalMethod": "t-test, 1 sided"}]}, {"type": "SECONDARY", "title": "Mean Non-transformed Amlodipine Plasma Concentration", "populationDescription": "Pharmacokinetic (PK) population: subset of overall trial population, consisting of participants at Investigational sites capable of obtaining PK blood samples in a protected light environment. No amlodipine PK statistical analyses were performed for the PK participants in the placebo+celecoxib and placebo+placebo arms.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/mL", "timeFrame": "24 hours post-dose on Day 14", "groups": [{"id": "OG000", "title": "Amlodipine+Celecoxib", "description": "Over-encapsulated 10 mg amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nOver-encapsulated 10 mg amlodipine besylate tablet: Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks\n\nOver-encapsulated 200 mg celecoxib capsule: Over-encapsulated 200 mg celecoxib capsule once a day for two weeks"}, {"id": "OG001", "title": "Amlodipine+Placebo", "description": "Over-encapsulated 10 mg amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks\n\nOver-encapsulated 10 mg amlodipine besylate tablet: Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks\n\nMatched placebo capsule for over-encapsulated celecoxib capsule: Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "20"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "15,800.83", "spread": "4,161.929"}, {"groupId": "OG001", "value": "23,453", "spread": "5,746.337"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "<0.001", "statisticalMethod": "t-test, 1 sided"}]}, {"type": "SECONDARY", "title": "Mean Non-transformed Celecoxib Plasma Concentration", "populationDescription": "PK population: subset of overall trial population, consisting of participants at Investigational sites capable of obtaining PK blood samples in a protected light environment. No celecoxib PK statistical analyses were performed for the PK participants in the amlodipine+placebo and placebo+placebo arms.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "24 hours post-dose on Day 14", "groups": [{"id": "OG000", "title": "Amlodipine+Celecoxib", "description": "Over-encapsulated 10 mg amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nOver-encapsulated 10 mg amlodipine besylate tablet: Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks\n\nOver-encapsulated 200 mg celecoxib capsule: Over-encapsulated 200 mg celecoxib capsule once a day for two weeks"}, {"id": "OG001", "title": "Placebo+Celecoxib", "description": "Matched placebo tablet for over-encapsulated amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nOver-encapsulated 200 mg celecoxib capsule: Over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nMatched placebo tablet for over-encapsulated amlodipine besylate tablet: Matched placebo tablet for over-encapsulated amlodipine besylate tablet once a day for two weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "139.708", "spread": "86.504"}, {"groupId": "OG001", "value": "138.667", "spread": "118.811"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "= 0.977", "statisticalMethod": "t-test, 1 sided"}]}, {"type": "SECONDARY", "title": "Mean Log-transformed Amlodipine Plasma Concentration", "populationDescription": "PK population: subset of overall trial population, consisting of participants at Investigational sites capable of obtaining PK blood samples in a protected light environment. No amlodipine PK statistical analyses were performed for the PK participants in the placebo+celecoxib and placebo+placebo arms.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "log(pg/mL)", "timeFrame": "24 hours post-dose on Day 14", "groups": [{"id": "OG000", "title": "Amlodipine+Celecoxib", "description": "Over-encapsulated 10 mg amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nOver-encapsulated 10 mg amlodipine besylate tablet: Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks\n\nOver-encapsulated 200 mg celecoxib capsule: Over-encapsulated 200 mg celecoxib capsule once a day for two weeks"}, {"id": "OG001", "title": "Amlodipine+Placebo", "description": "Over-encapsulated 10 mg amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks\n\nOver-encapsulated 10 mg amlodipine besylate tablet: Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks\n\nMatched placebo capsule for over-encapsulated celecoxib capsule: Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "20"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9.634", "spread": "0.268"}, {"groupId": "OG001", "value": "10.025", "spread": "0.310"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "<0.001", "statisticalMethod": "t-test, 1 sided"}]}, {"type": "SECONDARY", "title": "Mean Log-transformed Celecoxib Plasma Concentration", "populationDescription": "PK population: subset of overall trial population, consisting of participants at Investigational sites capable of obtaining PK blood samples in a protected light environment. No celecoxib PK statistical analyses were performed for the PK participants in the amlodipine+placebo and placebo+placebo arms.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "log(ng/mL)", "timeFrame": "24 hours post-dose on Day 14", "groups": [{"id": "OG000", "title": "Amlodipine+Celecoxib", "description": "Over-encapsulated 10 mg amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nOver-encapsulated 10 mg amlodipine besylate tablet: Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks\n\nOver-encapsulated 200 mg celecoxib capsule: Over-encapsulated 200 mg celecoxib capsule once a day for two weeks"}, {"id": "OG001", "title": "Placebo+Celecoxib", "description": "Matched placebo tablet for over-encapsulated amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nOver-encapsulated 200 mg celecoxib capsule: Over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nMatched placebo tablet for over-encapsulated amlodipine besylate tablet: Matched placebo tablet for over-encapsulated amlodipine besylate tablet once a day for two weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.785", "spread": "0.564"}, {"groupId": "OG001", "value": "4.636", "spread": "0.781"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "= 0.527", "statisticalMethod": "t-test, 1 sided"}]}, {"type": "SECONDARY", "title": "Mean Change in Average Daytime (9:00 to 21:00) Ambulatory Systolic Blood Pressure (SBPday) - Secondary Endpoint", "populationDescription": "ITT Population as described for primary outcome", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and 2 weeks", "groups": [{"id": "OG000", "title": "Amlodipine+Celecoxib", "description": "Over-encapsulated 10 mg amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nOver-encapsulated 10 mg amlodipine besylate tablet: Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks\n\nOver-encapsulated 200 mg celecoxib capsule: Over-encapsulated 200 mg celecoxib capsule once a day for two weeks"}, {"id": "OG001", "title": "Amlodipine+Placebo", "description": "Over-encapsulated 10 mg amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks\n\nOver-encapsulated 10 mg amlodipine besylate tablet: Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks\n\nMatched placebo capsule for over-encapsulated celecoxib capsule: Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks"}, {"id": "OG002", "title": "Placebo+Celecoxib", "description": "Matched placebo tablet for over-encapsulated amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nOver-encapsulated 200 mg celecoxib capsule: Over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nMatched placebo tablet for over-encapsulated amlodipine besylate tablet: Matched placebo tablet for over-encapsulated amlodipine besylate tablet once a day for two weeks"}, {"id": "OG003", "title": "Placebo+Placebo", "description": "Matched placebo tablet for over-encapsulated amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks\n\nMatched placebo capsule for over-encapsulated celecoxib capsule: Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks\n\nMatched placebo tablet for over-encapsulated amlodipine besylate tablet: Matched placebo tablet for over-encapsulated amlodipine besylate tablet once a day for two weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "45"}, {"groupId": "OG002", "value": "30"}, {"groupId": "OG003", "value": "26"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-10.6", "spread": "9.2"}, {"groupId": "OG001", "value": "-8.83", "spread": "8.13"}, {"groupId": "OG002", "value": "-0.5", "spread": "8.8"}, {"groupId": "OG003", "value": "-2.11", "spread": "8.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "t-test, 1 sided"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "t-test, 1 sided"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "t-test, 1 sided"}, {"groupIds": ["OG001", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "= 0.001", "statisticalMethod": "t-test, 1 sided"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "1 month", "eventGroups": [{"id": "EG000", "title": "Amlodipine+Celecoxib", "description": "Over-encapsulated 10 mg amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nOver-encapsulated 10 mg amlodipine besylate tablet: Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks\n\nOver-encapsulated 200 mg celecoxib capsule: Over-encapsulated 200 mg celecoxib capsule once a day for two weeks", "deathsNumAffected": 0, "deathsNumAtRisk": 49, "seriousNumAffected": 0, "seriousNumAtRisk": 49, "otherNumAffected": 17, "otherNumAtRisk": 49}, {"id": "EG001", "title": "Amlodipine+Placebo", "description": "Over-encapsulated 10 mg amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks\n\nOver-encapsulated 10 mg amlodipine besylate tablet: Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks\n\nMatched placebo capsule for over-encapsulated celecoxib capsule: Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks", "deathsNumAffected": 0, "deathsNumAtRisk": 45, "seriousNumAffected": 0, "seriousNumAtRisk": 45, "otherNumAffected": 17, "otherNumAtRisk": 45}, {"id": "EG002", "title": "Placebo+Celecoxib", "description": "Matched placebo tablet for over-encapsulated amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nOver-encapsulated 200 mg celecoxib capsule: Over-encapsulated 200 mg celecoxib capsule once a day for two weeks\n\nMatched placebo tablet for over-encapsulated amlodipine besylate tablet: Matched placebo tablet for over-encapsulated amlodipine besylate tablet once a day for two weeks", "deathsNumAffected": 0, "deathsNumAtRisk": 31, "seriousNumAffected": 0, "seriousNumAtRisk": 31, "otherNumAffected": 5, "otherNumAtRisk": 31}, {"id": "EG003", "title": "Placebo+Placebo", "description": "Matched placebo tablet for over-encapsulated amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks\n\nMatched placebo capsule for over-encapsulated celecoxib capsule: Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks\n\nMatched placebo tablet for over-encapsulated amlodipine besylate tablet: Matched placebo tablet for over-encapsulated amlodipine besylate tablet once a day for two weeks", "deathsNumAffected": 0, "deathsNumAtRisk": 27, "seriousNumAffected": 0, "seriousNumAtRisk": 27, "otherNumAffected": 6, "otherNumAtRisk": 27}], "otherEvents": [{"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 49}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 45}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 27}]}, {"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 49}, {"groupId": "EG001", "numEvents": 8, "numAffected": 7, "numAtRisk": 45}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 27}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 49}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 31}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 27}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 49}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 45}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 31}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 27}]}, {"term": "Gout", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 49}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 45}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 27}]}, {"term": "Joint swelling", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 49}, {"groupId": "EG001", "numEvents": 4, "numAffected": 3, "numAtRisk": 45}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 27}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 4, "numAtRisk": 49}, {"groupId": "EG001", "numEvents": 10, "numAffected": 6, "numAtRisk": 45}, {"groupId": "EG002", "numEvents": 3, "numAffected": 2, "numAtRisk": 31}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 27}]}, {"term": "Orthostatic hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (17.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 49}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 45}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 31}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 27}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "No limitations"}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "GT60", "restrictiveAgreement": true}, "pointOfContact": {"title": "J. Paul Waymack, M.D., Chief Medical Officer", "organization": "Kitov Pharmaceuticals, Ltd.", "email": "paul@kitovpharma.com", "phone": "(202) 965-2215"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M27583", "name": "Systolic Murmurs", "relevance": "LOW"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068579", "term": "Celecoxib"}, {"id": "D000017311", "term": "Amlodipine"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000000894", "term": "Anti-Inflammatory Agents, Non-Steroidal"}, {"id": "D000018712", "term": "Analgesics, Non-Narcotic"}, {"id": "D000000700", "term": "Analgesics"}, {"id": "D000018689", "term": "Sensory System Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000018501", "term": "Antirheumatic Agents"}, {"id": "D000052246", "term": "Cyclooxygenase 2 Inhibitors"}, {"id": "D000016861", "term": "Cyclooxygenase Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M277", "name": "Celecoxib", "asFound": "Air", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M4218", "name": "Anti-Inflammatory Agents, Non-Steroidal", "relevance": "LOW"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M4032", "name": "Analgesics", "relevance": "LOW"}, {"id": "M20786", "name": "Analgesics, Non-Narcotic", "relevance": "LOW"}, {"id": "M20604", "name": "Antirheumatic Agents", "relevance": "LOW"}, {"id": "M27009", "name": "Cyclooxygenase 2 Inhibitors", "relevance": "LOW"}, {"id": "M19209", "name": "Cyclooxygenase Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "ARhu", "name": "Antirheumatic Agents"}, {"abbrev": "Analg", "name": "Analgesics"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}]}}, "hasResults": true}